&nbsp;

CancerSystemPlanSummary.pdf

Jun 2019

Regimen

BORTDEXASELI

Cancer Type:

Hematologic,

Multiple Myeloma

Intent: Palliative

Funding:

New Drug Funding Program

Bortezomib - In Combination with Selinexor and Dexamethasone for Previously Treated Multiple Myeloma

ODB - General Benefit

dexamethasone

Exceptional Access Program

selinexor - In combination with bortezomib and dexamethasone for relapsed or refractory multiple myeloma

Drugs Used:

Quick Link(s):

Regimen Monograph

Nov 2024

Document

CancerSystemPlanSummary-6-19.pdf

Jun 2019

Document

CancerSystemPlanSummary-FR.pdf

Jun 2019

Document

CCOScreenForLifePrivacy.pdf

Jun 2019

Regimen

BOSU

Cancer Type:

Hematologic,

Leukemia - Chronic Myeloid (CML)

Intent: Palliative

Drugs Used:

bosutinib (Unfunded)

... Show more tags

Quick Link(s):

Regimen Monograph

Nov 2024

Regimen

CHOP

Cancer Type:

Hematologic,

Rare Diseases,

Sarcoma

Intent: Palliative

Funding:

ODB - General Benefit

prednisone

Drugs Used:

Quick Link(s):

Regimen Monograph

Jun 2019

Blog post

Camille G.: Using her cancer experience to help others

In 2012, I was diagnosed with cancer. I was 19 years old at the time, just days into my second year of university. Camille G. Patient & Family...

Jul 2019

Guidelines and Advice

Cancer Screening for Persons at Risk for or Affected with Lynch Syndrome Evidence Summary

Status: In-Review
ID: ES 15-16

Oct 2018

Chimeric Antigen Receptor (CAR) T-cell Therapy

Regimen

CRBPPACL+PEMB

Cancer Type:

Lung,

Non-Small Cell

Intent: Palliative

Funding:

New Drug Funding Program

Pembrolizumab - In Combination with Carboplatin and Paclitaxel for First-Line Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC)

Drugs Used: